Who Is Mark Rus, Chief Executive Officer of Delix Therapeutics
Executive leadership and perspectives on neuroplastogens at Delix Therapeutics.
Mark Rus is the Chief Executive Officer of Delix Therapeutics BioSpace.
At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.
As Chief Executive Officer, Rus has stated that Delix's Series C capital enables the company to advance Zalsupindole through Phase II Proof of Concept and expressed gratitude for Department of Defense grant support to develop non-hallucinogenic neuroplastogens BioSpace.
Where Mark Rus Is Now
Mark Rus serves as the Chief Executive Officer of Delix Therapeutics, as reported by pulse2.com and BioSpace.
Series C Capital and Zalsupindole
Mark Rus stated that Delix was proud to welcome new investors alongside the support of existing shareholders as the company entered its next stage of growth BioSpace.
Rus noted that Series C capital enables Delix to advance Zalsupindole through Phase II Proof of Concept, develop a broader pipeline of differentiated medicines, and build the company long term BioSpace.
Perspectives on Neuroplastogen Medicine
Rus stated that the validation of Delix's investor syndicate reflects growing conviction and data for neuroplastogens as an important new therapeutic class BioSpace.
He highlighted Delix's excitement to partner with investors who understand how to translate breakthrough neuroscience into medicines that reach patients at scale, and stated that Delix is positioned to define the next chapter of true neuroplastogen medicine BioSpace.
Department of Defense Grant and Hearing Loss Research
Rus expressed gratitude for Department of Defense grant support to identify and develop non-hallucinogenic neuroplastogens for neurological disorders including hearing loss FinancialContent.
Regarding hearing conditions, Rus stated that over 48 million Americans experience hearing loss in at least one ear, particularly active duty and retired military personnel FinancialContent. He also stated that hearing loss significantly affects patient quality of life and is linked to an increased risk of cognitive decline and neurodegeneration FinancialContent.
Frequently asked questions
Who is Mark Rus?
Mark Rus is the Chief Executive Officer of Delix Therapeutics BioSpace.
What is Mark Rus's title at Delix Therapeutics?
Mark Rus is the Chief Executive Officer (CEO) of Delix Therapeutics pulse2.com.
What did Mark Rus say Series C capital enables Delix to do?
Mark Rus noted that Series C capital enables Delix to advance Zalsupindole through Phase II Proof of Concept, develop a broader pipeline of differentiated medicines, and build the company long term BioSpace.
What did Mark Rus state about neuroplastogens as a therapeutic class?
Mark Rus stated that the validation of Delix's investor syndicate reflects growing conviction and data for neuroplastogens as an important new therapeutic class, and that Delix is positioned to define the next chapter of true neuroplastogen medicine BioSpace.
Why did Mark Rus express gratitude for Department of Defense support?
Mark Rus expressed gratitude for Department of Defense grant support to identify and develop non-hallucinogenic neuroplastogens for neurological disorders including hearing loss FinancialContent.
What has Mark Rus stated regarding hearing loss in Americans?
Mark Rus stated that over 48 million Americans experience hearing loss in at least one ear, particularly active duty and retired military personnel, and that hearing loss significantly affects quality of life and is linked to an increased risk of cognitive decline and neurodegeneration FinancialContent.
Sources
General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Mark Rus or Delix Therapeutics. See more people in psychedelic medicine.